EUHTA and its Impact on the UK

Thursday 28th November 2024 13:00 - 14:00 (GMT)


Masterclass Details:

Joint HTA, combined with prospective changes to the EU general pharmaceutical legislation, will require companies to devote enormous time and resources to adapting to new procedures.

Are you up to speed?

Trying to meet the needs of the EU’s 27 Member States is likely to take precedence over a UK market that is at risk of being marginalised. The relative timing of EU vs UK marketing authorisation will also likely increase the challenges for the UK market.

Once the first JCA reports are published, it remains to be seen how they will be used in practice in EU Member States. The potential use of the reports in the UK and countries outside of Europe will also be one to watch, and highlighted by our experienced panel in this must-attend 60-minute masterclass for LSAA members.

 

Key Learning Objectives:

  • Will the UK slip down the launch sequencing schedule?
  • What influence will NICE have in Europe in the age of joint clinical assessment?
  • How might NICE’s global standing be impacted by EU joint HTA?
  • How will HTA evolve across Europe and beyond?

 

Can’t make the date? Register and we’ll send you a link to the recording so you can watch it on demand in your own time.
  • Date and time

    28th Nov 2024 13:00 – 14:00 (GMT)

We work with more than 200 leading Life Sciences companies including:

Working with Life Science Access Academy, our company love the variety of the many courses that are on offer. The hour long courses on specific subjects are really useful on Friday lunchtimes for our field teams and gain a lot of interest.

Life Science Access Academy are also super flexible and helpful when it comes to tailoring some additional sessions to our needs.

Marsha Gray, Training Specialist

Boehringer Ingelheim Ltd

We have been partnered with LSAA for several years now which has enabled our team members to develop their competencies and capabilities.

With over 700 learning modules, regular webinars on highly relevant topics across the UK, the opportunity to engage with expert speakers after events and regular blogs and newsletters, the platform is a highly valued resource at Ferring.

The team also provides regular usage statistics so we can understand the hot topics in Ferring and enable colleagues to share knowledge and experience with each other.

Paul Runeckles, Director of Execution Excellence

Ferring

Frontier Medical has fully implemented, Life Science Access Academy allowing Sales and Marketing to utilise the system. Maximising on line learning for all remote staff stimulates a culture of self-development giving individuals the accountability and responsibility to broaden their skills set.

Life Science Access Academy training is topical and a good fit for the faced paced healthcare market.

Simon Warden, National Sales Manager

Frontier Medical Group

I have found the training via the Life Science Access Academy to be excellent and I know many of my colleagues have as well.

The content is always kept up to date and there is huge and interesting variety of topics covered. The site is curated in a way that makes it clear and easy to navigate. Also, the staff at Life Science access Academy are friendly and responsive and all the experts are always knowledgeable in their areas.

Richard Edmonds

Gedeon Richter Women's Health

The variety and relevancy of content brings value to many different roles across the healthcare industry.

I have also been overwhelmed by the way the Life Science Access Academy team have accommodated our own business needs, being sensitive yet responsive to helping us since its formation.

Robb Sayers, UK Capability Lead

ViiV Healthcare